293 related articles for article (PubMed ID: 23431957)
1. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
[TBL] [Abstract][Full Text] [Related]
3. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
[TBL] [Abstract][Full Text] [Related]
4. Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration.
Kristensen IB; Pedersen L; Rø TB; Christensen JH; Lyng MB; Rasmussen LM; Ditzel HJ; Børset M; Abildgaard N
Eur J Haematol; 2013 Sep; 91(3):196-200. PubMed ID: 23607294
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow expression of CCL3 is not correlated with the extent of lytic bone lesions.
Cohen Y; Gutwein O; Garach-Jehoshua O; Bar-Haim A; Kornberg A
Acta Haematol; 2014; 132(2):129-33. PubMed ID: 24556596
[No Abstract] [Full Text] [Related]
6. Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Leuk Lymphoma; 2014 Apr; 55(4):911-9. PubMed ID: 23915193
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease.
Wader KF; Fagerli UM; Børset M; Lydersen S; Hov H; Sundan A; Bofin A; Waage A
Histopathology; 2012 Feb; 60(3):443-51. PubMed ID: 22276607
[TBL] [Abstract][Full Text] [Related]
8. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).
Xiao R; Cerny J; Devitt K; Dresser K; Nath R; Ramanathan M; Rodig SJ; Chen BJ; Woda BA; Yu H
Am J Surg Pathol; 2014 Jun; 38(6):776-83. PubMed ID: 24705315
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor and its receptor c-met in multiple myeloma.
Börset M; Hjorth-Hansen H; Seidel C; Sundan A; Waage A
Blood; 1996 Nov; 88(10):3998-4004. PubMed ID: 8916966
[TBL] [Abstract][Full Text] [Related]
10. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
11. The HGF/Met/NF-κB Pathway Regulates RANKL Expression in Osteoblasts and Bone Marrow Stromal Cells.
Tsubaki M; Seki S; Takeda T; Chihara A; Arai Y; Morii Y; Imano M; Satou T; Shimomura K; Nishida S
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114380
[TBL] [Abstract][Full Text] [Related]
12. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
13. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity.
Ramani VC; Yang Y; Ren Y; Nan L; Sanderson RD
J Biol Chem; 2011 Feb; 286(8):6490-9. PubMed ID: 21131364
[TBL] [Abstract][Full Text] [Related]
14. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
15. Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease.
Teofili L; Di Febo AL; Pierconti F; Maggiano N; Bendandi M; Rutella S; Cingolani A; Di Renzo N; Musto P; Pileri S; Leone G; Larocca LM
Blood; 2001 Feb; 97(4):1063-9. PubMed ID: 11159538
[TBL] [Abstract][Full Text] [Related]
16. TRAIL produced from multiple myeloma cells is associated with osteolytic markers.
Kawano Y; Ueno S; Abe M; Kikukawa Y; Yuki H; Iyama K; Okuno Y; Mitsuya H; Hata H
Oncol Rep; 2012 Jan; 27(1):39-44. PubMed ID: 21993926
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia.
Zhelyazkova AG; Tonchev AB; Kolova P; Ivanova L; Gercheva L
Scand J Clin Lab Invest; 2008; 68(6):492-500. PubMed ID: 18609087
[TBL] [Abstract][Full Text] [Related]
18. CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance.
Carulli G; Buda G; Azzarà A; Ciancia EM; Sammuri P; Domenichini C; Guerri V; Petrini M
Acta Haematol; 2016; 135(1):11-4. PubMed ID: 26303094
[No Abstract] [Full Text] [Related]
19. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
20. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
